keyword
MENU ▼
Read by QxMD icon Read
search

Theodore hong

keyword
https://www.readbyqxmd.com/read/27916612/corrigendum-to-a-novel-multilocus-phylogenetic-estimation-reveals-unrecognized-diversity-in-asian-horned-toads-genus-megophrys-sensu-lato-anura-megophryidae-mol-phylogen-evol-106-2017-28-43
#1
Jin-Min Chen, Wei-Wei Zhou, Nikolay A Poyarkov, Bryan L Stuart, Rafe M Brown, Amy Lathrop, Ying-Yong Wang, Zhi-Yong Yuan, Ke Jiang, Mian Hou, Hong-Man Chen, Chatmongkon Suwannapoom, Sang Ngoc Nguyen, Tang Van Duong, Theodore J Papenfuss, Robert W Murphy, Ya-Ping Zhang, Jing Che
No abstract text is available yet for this article.
December 1, 2016: Molecular Phylogenetics and Evolution
https://www.readbyqxmd.com/read/27858558/understanding-the-paradigm-shift-in-pancreatic-cancer
#2
David P Ryan, Theodore S Hong
No abstract text is available yet for this article.
October 2016: Journal of Oncology Practice
https://www.readbyqxmd.com/read/27846142/predictors-of-early-mortality-after-surgical-resection-of-pancreatic-adenocarcinoma-in-the-era-of-neoadjuvant-treatment
#3
Ryan D Nipp, Andrea Zanconato, Hui Zheng, Cristina R Ferrone, Keith D Lillemoe, Jennifer Y Wo, Theodore S Hong, Jeffrey W Clark, David P Ryan, Carlos Fernandez-Del Castillo
OBJECTIVES: Neoadjuvant treatments are increasingly used for patients with pancreatic ductal adenocarcinoma (PDAC), yet some experience early mortality after resection. We sought to identify predictors of early mortality after PDAC resection and determine their interaction with neoadjuvant therapy. METHODS: We performed a retrospective study of patients with PDAC resection from March 2011 to March 2014. We compared those who died within one year after surgery to those living beyond 1 year, and those who received neoadjuvant therapy to those taken directly to surgery...
November 11, 2016: Pancreas
https://www.readbyqxmd.com/read/27749696/hyperspectral-autofluorescence-imaging-of-drusen-and-retinal-pigment-epithelium-in-donor-eyes-with-age-related-macular-degeneration
#4
Yuehong Tong, Tal Ben Ami, Sungmin Hong, Rainer Heintzmann, Guido Gerig, Zsolt Ablonczy, Christine A Curcio, Thomas Ach, R Theodore Smith
PURPOSE: To elucidate the molecular pathogenesis of age-related macular degeneration (AMD) and interpretation of fundus autofluorescence imaging, the authors identified spectral autofluorescence characteristics of drusen and retinal pigment epithelium (RPE) in donor eyes with AMD. METHODS: Macular RPE/Bruch membrane flat mounts were prepared from 5 donor eyes with AMD. In 12 locations (1-3 per eye), hyperspectral autofluorescence images in 10-nm-wavelength steps were acquired at 2 excitation wavelengths (λex 436, 480 nm)...
September 30, 2016: Retina
https://www.readbyqxmd.com/read/27740973/intraoperative-radiotherapy-in-the-era-of-intensive-neoadjuvant-chemotherapy-and-chemoradiotherapy-for-pancreatic-adenocarcinoma
#5
Florence K Keane, Jennifer Y Wo, Cristina R Ferrone, Jeffrey W Clark, Lawrence S Blaszkowsky, Jill N Allen, Eunice L Kwak, David P Ryan, Keith D Lillemoe, Carlos Fernandez-Del Castillo, Theodore S Hong
OBJECTIVES: Improved outcomes with FOLFIRINOX or gemcitabine with nab-paclitaxel in the treatment of metastatic pancreatic adenocarcinoma (PDAC) have prompted incorporation of these regimens into neoadjuvant treatment of locally advanced unresectable PDAC. Whereas some patients remain unresectable on surgical exploration, others are able to undergo resection after intensive neoadjuvant treatment. We evaluated outcomes and toxicity associated with use of intensive neoadjuvant treatment followed by intraoperative radiotherapy (IORT) in combination with resection or exploratory laparotomy...
October 12, 2016: American Journal of Clinical Oncology
https://www.readbyqxmd.com/read/27736041/comparative-safety-and-effectiveness-of-denosumab-versus-zoledronic-acid-in-patients-with-osteoporosis-a-cohort-study
#6
Nam-Kyong Choi, Daniel H Solomon, Theodore N Tsacogianis, Joan E Landon, Hong Ji Song, Seoyoung C Kim
Limited head-to-head comparative safety and effectiveness data exist between denosumab and zoledronic acid in real-world healthcare. We aimed to examine the safety and effectiveness of denosumab compared to zoledronic acid with regard to risk of serious infection and cardiovascular disease (CVD) and osteoporotic fracture. We conducted a cohort study using claims data (2009-2013) from a US commercial insurance. We included patients aged ≥50 years who newly initiated denosumab or zoledronic acid. The primary outcomes were 1) hospitalization for serious infection, 2) composite CVD endpoint including myocardial infarction, stroke, coronary revascularization, and heart failure and 3) non-vertebral osteoporotic fracture including hip, wrist, forearm and pelvic fracture...
October 13, 2016: Journal of Bone and Mineral Research: the Official Journal of the American Society for Bone and Mineral Research
https://www.readbyqxmd.com/read/27714434/contemporary-experience-with-high-dose-interleukin-2-therapy-and-impact-on-survival-in-patients-with-metastatic-melanoma-and-metastatic-renal-cell-carcinoma
#7
Ajjai Alva, Gregory A Daniels, Michael K K Wong, Howard L Kaufman, Michael A Morse, David F McDermott, Joseph I Clark, Sanjiv S Agarwala, Gerald Miletello, Theodore F Logan, Ralph J Hauke, Brendan Curti, John M Kirkwood, Rene Gonzalez, Asim Amin, Mayer Fishman, Neeraj Agarwal, James N Lowder, Hong Hua, Sandra Aung, Janice P Dutcher
High-dose interleukin-2 (HD IL-2) was approved for treatment of metastatic renal cell carcinoma (mRCC) in 1992 and for metastatic melanoma (mM) in 1998, in an era predating targeted therapies and immune checkpoint inhibitors. The PROCLAIM(SM) registry was established to collect and analyze data for patients treated with HD IL-2 in the current era. This analysis includes 170 patients with mM and 192 patients with mRCC treated between 2005 and 2012 with survival data current as of July 27, 2015. For patients with mM, complete response (CR) was observed in 5 %, partial response (PR) in 10 %, stable disease (SD) in 22 %, and 63 % had progressive disease (PD)...
December 2016: Cancer Immunology, Immunotherapy: CII
https://www.readbyqxmd.com/read/27622725/a-novel-multilocus-phylogenetic-estimation-reveals-unrecognized-diversity-in-asian-horned-toads-genus-megophrys-sensu-lato-anura-megophryidae
#8
Jin-Min Chen, Wei-Wei Zhou, Nikolay A Poyarkov, Bryan L Stuart, Rafe M Brown, Amy Lathrop, Ying-Yong Wang, Zhi-Yong Yuan, Ke Jiang, Mian Hou, Hong-Man Chen, Chatmongkon Suwannapoom, Sang Ngoc Nguyen, Tang Van Duong, Theodore J Papenfuss, Robert W Murphy, Ya-Ping Zhang, Jing Che
The horned toad assemblage, genus Megophrys sensu lato, currently includes three groups previously recognized as the genera Atympanophrys, Xenophrys and Megophrys sensu stricto. The taxonomic status and species composition of the three groups remain controversial due to conflicting phenotypic analyses and insufficient phylogenetic reconstruction; likewise, the position of the monotypic Borneophrys remains uncertain with respect to the horned toads. Further, the diversity of the horned toads remains poorly understood, especially for widespread species...
September 10, 2016: Molecular Phylogenetics and Evolution
https://www.readbyqxmd.com/read/27493895/liver-directed-radiotherapy-for-hepatocellular-carcinoma
#9
REVIEW
Florence K Keane, Jennifer Y Wo, Andrew X Zhu, Theodore S Hong
BACKGROUND: The incidence of hepatocellular carcinoma (HCC) continues to increase world-wide. Many patients present with advanced disease with extensive local tumor or vascular invasion and are not candidates for traditionally curative therapies such as orthotopic liver transplantation (OLT) or resection. Radiotherapy (RT) was historically limited by its inability to deliver a tumoricidal dose; however, modern RT techniques have prompted renewed interest in the use of liver-directed RT to treat patients with primary hepatic malignancies...
July 2016: Liver Cancer
https://www.readbyqxmd.com/read/27469583/mycophenolate-mofetil-versus-oral-cyclophosphamide-in-scleroderma-related-interstitial-lung-disease-sls-ii-a-randomised-controlled-double-blind-parallel-group-trial
#10
Donald P Tashkin, Michael D Roth, Philip J Clements, Daniel E Furst, Dinesh Khanna, Eric C Kleerup, Jonathan Goldin, Edgar Arriola, Elizabeth R Volkmann, Suzanne Kafaja, Richard Silver, Virginia Steen, Charlie Strange, Robert Wise, Fredrick Wigley, Maureen Mayes, David J Riley, Sabiha Hussain, Shervin Assassi, Vivien M Hsu, Bela Patel, Kristine Phillips, Fernando Martinez, Jeffrey Golden, M Kari Connolly, John Varga, Jane Dematte, Monique E Hinchcliff, Aryeh Fischer, Jeffrey Swigris, Richard Meehan, Arthur Theodore, Robert Simms, Suncica Volkov, Dean E Schraufnagel, Mary Beth Scholand, Tracy Frech, Jerry A Molitor, Kristin Highland, Charles A Read, Marvin J Fritzler, Grace Hyun J Kim, Chi-Hong Tseng, Robert M Elashoff
BACKGROUND: 12 months of oral cyclophosphamide has been shown to alter the progression of scleroderma-related interstitial lung disease when compared with placebo. However, toxicity was a concern and without continued treatment the efficacy disappeared by 24 months. We hypothesised that a 2 year course of mycophenolate mofetil would be safer, better tolerated, and produce longer lasting improvements than cyclophosphamide. METHODS: This randomised, double-blind, parallel group trial enrolled patients from 14 US medical centres with scleroderma-related interstitial lung disease meeting defined dyspnoea, pulmonary function, and high-resolution CT (HRCT) criteria...
September 2016: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/27459983/what-s-the-best-way-to-treat-ge-junction-tumors-approach-like-gastric-cancer
#11
John T Mullen, Eunice L Kwak, Theodore S Hong
The debate as to the optimal classification, staging, and treatment of gastroesophageal junction (GEJ) tumors wages on, and one must acknowledge that there is no "one-size-fits-all" approach. However, in this review we are charged with defending the position that all GEJ tumors are best treated like gastric cancer. We submit that, as stated, this is not a defensible position and that a clear definition of terms is warranted. Given the rarity of squamous cell carcinoma and the dramatic rise in incidence of adenocarcinoma of the GEJ in the West, we define GEJ "tumors" to mean adenocarcinomas of the GEJ...
November 2016: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/27341601/combined-modality-therapy-for-rectal-cancer
#12
Sagar A Patel, David P Ryan, Theodore S Hong
The primary therapy for any potentially curative rectal cancer is surgery. For locally advanced tumors (i.e., T3-4 and/or node positive), the very high rate of local and distant recurrences has necessitated a standard adjuvant regimen of preoperative chemoradiation and postoperative chemotherapy. Several controversies regarding this approach remain, including the technique and fractionation scheme of radiation therapy prior to surgery, the choice of concomitant chemotherapy, and whether all patients require postoperative systemic therapy...
May 2016: Cancer Journal
https://www.readbyqxmd.com/read/27247221/potentially-curable-pancreatic-cancer-american-society-of-clinical-oncology-clinical-practice-guideline
#13
Alok A Khorana, Pamela B Mangu, Jordan Berlin, Anitra Engebretson, Theodore S Hong, Anirban Maitra, Supriya G Mohile, Matthew Mumber, Richard Schulick, Marc Shapiro, Susan Urba, Herbert J Zeh, Matthew H G Katz
PURPOSE: To provide evidence-based recommendations to oncologists and others on potentially curative therapy for patients with localized pancreatic cancer. METHODS: ASCO convened a panel of medical oncology, radiation oncology, surgical oncology, palliative care, and advocacy experts and conducted a systematic review of literature from January 2002 to June 2015. Outcomes included overall survival, disease-free survival, progression-free survival, and adverse events...
July 20, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/27238474/advancing-techniques-of-radiation-therapy-for-rectal-cancer
#14
REVIEW
Sagar A Patel, Jennifer Y Wo, Theodore S Hong
Since the advent of radiation therapy for rectal cancer, there has been continual investigation of advancing technologies and techniques that allow for improved dose conformality to target structures while limiting irradiation of surrounding normal tissue. For locally advanced disease, intensity modulated and proton beam radiation therapy both provide more highly conformal treatment volumes that reduce dose to organs at risk, though the clinical benefit in terms of toxicity reduction is unclear. For early stage disease, endorectal contact therapy and high-dose rate brachytherapy may be a definitive treatment option for patients who are poor operative candidates or those with low-lying tumors that desire sphincter-preservation...
July 2016: Seminars in Radiation Oncology
https://www.readbyqxmd.com/read/27160474/folfirinox-for-locally-advanced-pancreatic-cancer-a-systematic-review-and-patient-level-meta-analysis
#15
Mustafa Suker, Berend R Beumer, Eran Sadot, Lysiane Marthey, Jason E Faris, Eric A Mellon, Bassel F El-Rayes, Andrea Wang-Gillam, Jill Lacy, Peter J Hosein, Sing Yu Moorcraft, Thierry Conroy, Florian Hohla, Peter Allen, Julien Taieb, Theodore S Hong, Ravi Shridhar, Ian Chau, Casper H van Eijck, Bas Groot Koerkamp
BACKGROUND: 35% of patients with pancreatic cancer have unresectable locally advanced disease at diagnosis. Several studies have examined systemic chemotherapy with FOLFIRINOX (leucovorin and fluorouracil plus irinotecan and oxaliplatin) in patients with locally advanced pancreatic cancer. We aimed to assess the effectiveness of FOLFIRINOX as first-line treatment in this patient population. METHODS: We systematically searched Embase, MEDLINE (OvidSP), Web of Science, Scopus, PubMed Publisher, Cochrane, and Google Scholar from July 1, 1994, to July 2, 2015, for studies of treatment-naive patients of any age who received FOLFIRINOX as first-line treatment of locally advanced pancreatic cancer...
June 2016: Lancet Oncology
https://www.readbyqxmd.com/read/27084631/disruption-of-slx4-mus81-function-increases-the-relative-biological-effectiveness-of-proton-radiation
#16
Qi Liu, Tracy S A Underwood, Jong Kung, Meng Wang, Hsiao-Ming Lu, Harald Paganetti, Kathryn D Held, Theodore S Hong, Jason A Efstathiou, Henning Willers
PURPOSE: Clinical proton beam therapy has been based on the use of a generic relative biological effectiveness (RBE) of ∼1.1. However, emerging data have suggested that Fanconi anemia (FA) and homologous recombination pathway defects can lead to a variable RBE, at least in vitro. We investigated the role of SLX4 (FANCP), which acts as a docking platform for the assembly of multiple structure-specific endonucleases, in the response to proton irradiation. METHODS AND MATERIALS: Isogenic cell pairs for the study of SLX4, XPF/ERCC1, MUS81, and SLX1 were irradiated at the mid-spread-out Bragg peak of a clinical proton beam (linear energy transfer 2...
May 1, 2016: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/27084053/comparison-of-clinical-features-in-blacks-versus-whites-with-hypertrophic-cardiomyopathy
#17
Lars L Sorensen, Aurelio Pinheiro, Veronica Lea Dimaano, Iraklis Pozios, Alexandra Nowbar, Hongyun Liu, Hong-Chang Luo, Xiaoping Lin, Niels T Olsen, Thomas F Hansen, Peter Sogaard, Maria R Abraham, Theodore P Abraham
To date, there has not been a large systematic examination of the hypertrophic cardiomyopathy (HC) phenotype in blacks versus whites. In this study, we investigate differences in presentation of HC between blacks and whites. We included 441 consecutive patients with HC seen at the Johns Hopkins HC clinic in the period from February 2005 to June 2012. We compared 76 blacks for clinical presentation, electrocardiogram, exercise capacity, left ventricular morphology, and hemodynamics by echocardiography to 365 whites...
June 1, 2016: American Journal of Cardiology
https://www.readbyqxmd.com/read/27032689/a-protein-and-mrna-expression-based-classification-of-gastric-cancer
#18
Namrata Setia, Agoston T Agoston, Hye S Han, John T Mullen, Dan G Duda, Jeffrey W Clark, Vikram Deshpande, Mari Mino-Kenudson, Amitabh Srivastava, Jochen K Lennerz, Theodore S Hong, Eunice L Kwak, Gregory Y Lauwers
The overall survival of gastric carcinoma patients remains poor despite improved control over known risk factors and surveillance. This highlights the need for new classifications, driven towards identification of potential therapeutic targets. Using sophisticated molecular technologies and analysis, three groups recently provided genetic and epigenetic molecular classifications of gastric cancer (The Cancer Genome Atlas, 'Singapore-Duke' study, and Asian Cancer Research Group). Suggested by these classifications, here, we examined the expression of 14 biomarkers in a cohort of 146 gastric adenocarcinomas and performed unsupervised hierarchical clustering analysis using less expensive and widely available immunohistochemistry and in situ hybridization...
July 2016: Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc
https://www.readbyqxmd.com/read/26972647/irradiation-of-fdg-pet-defined-active-bone%C3%A2-marrow-subregions-and-acute-hematologic%C3%A2-toxicity-in-anal-cancer-patients-undergoing-chemoradiation
#19
Brent S Rose, Kyung-Wook Jee, Andrzej Niemierko, Janet E Murphy, Lawrence S Blaszkowsky, Jill N Allen, Leslie K Lee, Yingbing Wang, Lorraine C Drapek, Theodore S Hong, Jennifer Y Wo
PURPOSE: Irradiation of pelvic bone marrow (BM) has been correlated with hematologic toxicity (HT) in patients undergoing chemoradiation for anal cancer. We hypothesized that irradiation of hematologically active bone marrow (ABM) subregions defined by fluorodeoxyglucose (FDG) positron emission tomography (PET) is a principal cause of radiation-associated HT. METHODS AND MATERIALS: The cohort included 45 patients with nonmetastatic anal cancer who underwent FDG-PET imaging prior to definitive chemoradiation with mitomycin-C and 5-fluorouracil...
March 15, 2016: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/26922700/appropriate-customization-of-radiation-therapy-for-stage-ii-and-iii-rectal-cancer-executive-summary-of-an-astro-clinical-practice-statement-using-the-rand-ucla-appropriateness-method
#20
Karyn A Goodman, Caroline E Patton, George A Fisher, Sarah E Hoffe, Michael G Haddock, Parag J Parikh, John Kim, Nancy N Baxter, Brian G Czito, Theodore S Hong, Joseph M Herman, Christopher H Crane, Karen E Hoffman
PURPOSE: To summarize results of a Clinical Practice Statement on radiation therapy for stage II-III rectal cancer, which addressed appropriate customization of (neo)adjuvant radiation therapy and use of non-surgical therapy for patients who are inoperable or refuse abdominoperineal resection. METHODS AND MATERIALS: The RAND/University of California, Los Angeles, Appropriateness Method was applied to combine current evidence with multidisciplinary expert opinion...
May 2016: Practical Radiation Oncology
keyword
keyword
85473
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"